中文名稱:Captopril | 英文名稱:Captopril |
CAS:62571-86-2 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 62571-86-2 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號 | 型號 |
Captopril | 100mg 500mg | 62571-86-2 | EY-Y0164012 |
Cas No.62571-86-2
別名 N/A
化學(xué)名 (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
分子式 C9H15NO3S
分子量 217.3
溶解度 ≥ 21.7 mg/mL in DMSO, ≥ 105.2 mg/mL in EtOH with ultrasonic, ≥ 48.6 mg/mL in H2O with ultrasonic
儲存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
Captopril is an inhibitor of Angiotensin-I-converting enzyme (ACE) with IC50 value of 6nM [1].
Captopril is an old drug with antihypertensive efficacy commonly used in the control of blood pressure. Captopril is found to be an ACE inhibitor in all species studied. Administration of captopril inhibits the pressor response to intravenously administered angiotensin I but not that induced by angiotensin II both in normal human beings and in conscious normotensive rabbits. Captopril is proven to be a useful alternative to combination antihypertensive therapy in
the patients with resistant hypertension [2].
Captopril is also found to have anticancer activity. It can significantly reduce tumor growth without toxicity in athymic mice bearing LNM35 human lung cells xenografts. It is proven that captopril affects cell growth through inducing apoptosis [3].
References:
[1] FitzGerald RJ, Meisel H. Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr. 2000 Nov;84
[2] Bravo EL, Tarazi RC. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension. 1979 Jan-Feb;1(1):39-46.
[3] Attoub S, Gaben AM, Al-Salam S, Al Sultan MA, John A, Nicholls MG, Mester J, Petroianu G. Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci. 2008 Sep;1138:65-72.
成立日期 | 2014-06-05 (11年) | 注冊資本 | 100 |
員工人數(shù) | 50-100人 | 年營業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP12年
|
上海弘邦醫(yī)藥科技有限公司
|
2024-12-24 | |
詢價 |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2024-12-24 | |
詢價 |
VIP1年
|
銘龍(咸寧)醫(yī)藥有限公司
|
2024-12-24 | |
詢價 |
VIP6年
|
武漢鼎信通藥業(yè)有限公司
|
2024-12-24 | |
¥800 |
VIP12年
|
湖北威德利化學(xué)科技有限公司
|
2024-12-24 | |
¥750 |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2024-12-24 | |
¥828 |
VIP4年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2024-12-24 | |
詢價 |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2024-12-24 | |
詢價 |
VIP6年
|
湖北威德利化學(xué)試劑有限公司
|
2024-12-23 | |
詢價 |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2024-12-23 |